Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX 株式レポート

時価総額:US$262.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Black Diamond Therapeutics マネジメント

マネジメント 基準チェック /24

Black Diamond Therapeutics'の CEO はMark Vellecaで、 Sep2023年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 3.39Mで、 5.3%給与と94.7%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.083%を直接所有しており、その価値は$ 254.47K 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4年です。

主要情報

Mark Velleca

最高経営責任者

US$3.4m

報酬総額

CEO給与比率5.3%
CEO在任期間less than a year
CEOの所有権0.08%
経営陣の平均在職期間2.5yrs
取締役会の平均在任期間4yrs

経営陣の近況

Recent updates

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05
What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01
Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond nominates development candidate for glioblastoma program

Nov 20

Black Diamond Therapeutics EPS beats by $0.02

Nov 10

Black Diamond Therapeutics: One To Watch In Precision Oncology Space

Oct 23

CEO報酬分析

Black Diamond Therapeutics の収益と比較して、Mark Velleca の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$3mUS$180k

-US$82m

Sep 30 2023n/an/a

-US$84m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$87m

Dec 31 2022US$65kn/a

-US$91m

Sep 30 2022n/an/a

-US$96m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$204kn/a

-US$126m

報酬と市場: Markの 総報酬 ($USD 3.39M ) は、 US市場 ($USD 2.45M ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Mark Velleca (60 yo)

less than a year

在職期間

US$3,387,383

報酬

Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Velleca
CEO, President & Chairmanless than a yearUS$3.39m0.083%
$ 216.8k
David M. Epstein
Co-Founder & Directorno dataUS$2.02m1.62%
$ 4.3m
Fang Ni
CFO, Principal Financial Officer and Chief Business Officer2.6yrsUS$1.49m0.23%
$ 598.0k
Sergey Yurasov
Chief Medical Officer2yrsUS$1.23m0%
$ 0
Elizabeth Buck
Co-Founder & Chief Scientific Officer2.8yrsUS$347.30kデータなし
Brent Hatzis-Schoch
COO & General Counsel5.1yrsUS$911.23k0.015%
$ 39.1k
Elizabeth Montgomery
Chief People Officer2.3yrsデータなしデータなし
Melanie Morrison
Chief Development Officer1.6yrsデータなしデータなし
Erika Jones
Senior VP of Finance & Corporate Controller3.4yrsデータなし0.0054%
$ 14.2k

2.5yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: BDTXの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Mark Velleca
CEO, President & Chairman2.8yrsUS$3.39m0.083%
$ 216.8k
David M. Epstein
Co-Founder & Director7.8yrsUS$2.02m1.62%
$ 4.3m
Ali Behbahani
Independent Director5.5yrsUS$68.14k0.097%
$ 254.3k
Garry Menzel
Independent Director7.3yrsUS$75.35k0.14%
$ 357.2k
Kapil Dhingra
Independent Director3.4yrsUS$109.35k0.018%
$ 46.6k
Samarth Kulkarni
Lead Independent Director4.6yrsUS$59.35k0%
$ 0
Prakash Raman
Independent Directorless than a yearデータなし0.0041%
$ 10.7k
Shannon Campbell
Independent Directorless than a yearデータなし0.0036%
$ 9.4k

4.0yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: BDTXの 取締役会経験豊富 であると考えられます ( 4年の平均在任期間)。